## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.5% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (52% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($560.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Generate Investment Management Ltd Invests $7.47 Million in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251231T113616 | Somewhat-Bullish | Relevance: 100%
- Generate Investment Management Ltd reported acquiring a new stake of 15,403 shares in Thermo Fisher Scientific Inc., valued at approximately $7.47 million during the third quarter. Institutional ownership of TMO now stands at about 89.23%, despite recent net selling by company insiders. Thermo Fisher Scientific has outperformed Q3 expectations and analysts have a "Moderate Buy" consensus rating with an average target price of $616.60.

**2. BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View**
- Source: Insider Monkey | 20251230T230944 | Bullish | Relevance: 100%
- Bank of America has raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650, maintaining a Buy rating, anticipating a biopharma recovery in 2026. The firm believes easing headwinds and a rebound in R&D spending will benefit companies like Thermo Fisher. This outlook also follows Thermo Fisher's recent acquisition of Clario for up to $9.4 billion, aimed at strengthening its clinical trial research business.

**3. Thermo Fisher Q4 2025 Earnings: Forecast, Date, and Analyst Outlook - News and Statistics**
- Source: IndexBox | 20251230T110944 | Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (TMO) is projected to announce its fiscal fourth-quarter earnings for 2025 on January 29, 2026, with analysts anticipating a 5.6% increase in EPS to $6.44 per share. Despite underperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund over the past year due to challenges in China, pricing pressures, and cautious spending, the company's Q3 results surpassed expectations. Analysts currently hold a "Strong Buy" consensus rating for TMO, with an average price target indicating an 8.9% upside.

**4. Smith Salley Wealth Management Purchases 1,771 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251231T113616 | Somewhat-Bullish | Relevance: 100%
- Smith Salley Wealth Management increased its holdings in Thermo Fisher Scientific Inc. by 3.1% in the third quarter, acquiring an additional 1,771 shares. This brings their total stake to 58,846 shares valued at $28.541 million, making TMO their 18th-largest position. Despite significant insider selling over the past 90 days, institutional ownership of Thermo Fisher Scientific remains high at 89.23%.

**5. Calamos Advisors LLC Grows Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251231T095823 | Bullish | Relevance: 100%
- Calamos Advisors LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.8% in Q3, now owning 147,700 shares valued at approximately $71.64 million. Despite this, company insiders have been net sellers, with CEO Marc N. Casper selling 17,104 shares and VP Lisa P. Britt selling 10,225 shares. The medical research company reported strong Q3 earnings, beating expectations, and authorized a $5.0 billion share buyback program.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.7B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.4% to 1.5% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum. RSI neutral at 54. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.53% (CS: 78) | Neutral |
| RSI_14 | 54.0 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.194x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $579.52
- **Stop Loss:** $560.16 (3.3% risk)
- **Target:** $598.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $42,884.48
- **Portfolio %:** 42.88%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*